Overtaken by their own success: management is reworking company plans mid-course because real business arrived bigger or
The model's full reasoning — Q3 2018 call → NOWe need to determine if the transcript reveals that the company's own working assumptions have been overtaken by what is actually happening, and that management has already changed something concrete in response, and that they are still catching up. Let's analyze the transcript for any such phenomenon. The company is Agios, with products like TIBSOVO (ivosidenib) and IDHIFA. The call covers Q3 2018 results, including the launch of TIBSOVO. Key points: The launch of TIBSOVO in July 2018. Steve Hoerter, Chief Commercial Officer, gives an update. He says: "Since our launch in July, our team of senior hematology sales consultants has had approximately 2,000 customer interactions, raising awareness of TIBSOVO and educating physicians on how this novel first-in-class precision medicine can be used to benefit their patients with relapsed or refractory AML with an IDH mutation. Increasing testing rates of the IDH mutation is a key strategic imperative for the adoption of both of our IDH inhibitors, and we’re encouraged with the steady growth, driven by our field team throughout this year. According to market research from August, just after TIBSOVO launched, approximately 80% of physicians were testing their patients for the IDH1 and IDH2 mutations. We believe the academic centers are screening the vast majority of their patients for actionable mutations, such as IDH. The community is typically behind academic centers in this respect and our focus is on improving IDH testing rates among these prescribers. With respect to the physician awareness, we’re encouraged that awareness of TIBSOVO is already above 90%, which compares favorably to a 50% awareness of IDHIFA at a similar time in its launch. During the first two months of the TIBSOVO launch, we estimate over 100 unique prescribers have written a prescription for our medicine, and we are pleased with the uptake we are seeing. Consistent with our early IDHIFA experience, we expect that the initial patients treated with TIBSOVO will be more advanced in their disease. And as the launch progresses and the patient mix evolves, we expect the treatment duration to increase." This indicates that the launch is going well, with awareness and testing rates higher than expected compared to IDHIFA.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| EMR | Emerson Electric Co. | Q3 2021 | 2021-08-04 | B+ |
| DGX | Quest Diagnostics Incorporated | Q2 2021 | 2021-07-22 | B+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
EMR · Q3 2021 → YESThe question is whether management reveals that the company's own working assumptions have been overtaken by actual events, they've already changed something concrete, and they're still catching up. ...YES The transcript shows management confirming that actual operating activity (sales/orders growth, demand recovery, project wins) has outrun their own prior expectations and plans for the quarter and year. They explicitly note sales/orders "ahead of our expectations," "exceeding our management expectations," and a "V-shaped demand recovery" plus 26% trailing orders that accelerated beyond what was assumed. In response, they have already taken concrete actions: ramping up capacity at plants in the U.S.
MNKD · Q4 2023 → YESThe question is whether management reveals that the company's own working assumptions have been overtaken by actual events, they've already changed something concrete, and they're still catching up. ...YES The transcript shows management confirming that Tyvaso DPI demand and production have run ahead of their own earlier assumptions: the launch was “under-forecast,” actual patient uptake and volumes exceeded what they had planned, and they had to “work incredibly hard” and add capacity (high-speed fill line) to keep up 100 % of demand. They have already acted by completing the new line qualification, starting PPQ runs, and ramping production “much higher” volumes in Q1/Q2.
AOSL · Q2 2018 → YESThe question is whether management reveals that the company's own working assumptions have been overtaken by actual events, they've already changed something concrete, and they're still catching up. ...YES The transcript shows management describing a clear upward surprise in demand for new products that has already outrun their existing capacity plans ("demand for our new products has increased in the last year or so... capacity constraints have caused us to forgo potential revenue... tens of millions of dollars"), with the Chongqing JV built specifically to address it.